• 1
    Baxter C, Jones R, Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ 1998; 317: 11345.
  • 2
    Larsen J, Andersen M, Kragstrup J, Gram LF. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993–1998) in a Danish population. Eur J Clin Pharmacol 2001; 57: 3438.
  • 3
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13839.
  • 4
    Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 13017.
  • 5
    Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 10019.
  • 6
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 134957.
  • 7
    Siegel D, Lopez J, Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 2000; 108: 4969.
  • 8
    Martikainen J, Klaukka T, Reunanen A, Peura S, Wahlroos H. Recent trends in the consumption of lipid-lowering drugs in Finland. J Clin Epidemiol 1996; 49: 14537.
  • 9
    Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, Chinellato A. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994–2003. Eur J Clin Pharmacol 2007; 63: 197203.
  • 10
    Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J 2001; 141: 95763.
  • 11
    EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 9951001.
  • 12
    Magrini N, Einarson T, Vaccheri A, McManus P, Montanaro N, Bergman U. Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. Eur J Clin Pharmacol 1997; 53: 1859.
  • 13
    Larsen J, Vaccheri A, Andersen M, Montanaro N, Bergman U. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 46371.
  • 14
    Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius AJ, De Boer A. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 2002; 53: 37985.
  • 15
    Riahi S, Fonager K, Toft E, Hvilsted-Rasmussen L, Bendsen J, Paaske Johnsen S, Sorensen HT. Use of lipid-lowering drugs during 1991–98 in Northern Jutland, Denmark. Br J Clin Pharmacol 2001; 52: 30711.
  • 16
    Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol 2005; 60: 54351.
  • 17
    Nordic Medico Statistical Committee (Nomesco). Medicines Consumption in the Nordic Countries 1999–2003. Copenhagen, Denmark: Nomesco, 2004.
  • 18
    The National Agency for Medicines and the Social Insurance Institution. Finnish Statistics on Medicines 2005. Helsinki, Finland: National Agency for Medicines and the Social Insurance Institution, 2006.
  • 19
    The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses 2005. Helsinki, Finland: National Agencies for Medicines, 2005.
  • 20
    The National Agency for Medicines. Classification of Medicines and the Defined Daily Doses 1995. Helsinki, Finland: National Agencies for Medicines, 1995.
  • 21
    Kattainen A, Salomaa V, Härkänen T, Jula A, Kaaja R, Kesäniemi YA, Kähönen M, Moilanen L, Nieminen MS, Aromaa A, Reunanen A. Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J 2006; 27: 296301.
  • 22
    Pajunen P, Pääkkönen R, Juolevi A, Hämäläinen H, Keskimäki I, Laatikainen T, Moltchanov V, Niemi M, Rintanen H, Salomaa V. Trends in fatal and non-fatal coronary heart disease events in Finland during 1991–2001. Scand Cardiovasc J 2004; 38: 3404.
  • 23
    Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 162330.
  • 24
    Heart protection Study Collaborative Group. MRC/BHF heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 721.
  • 25
    Suomen Sisätautilääkärien yhdistyksen asettama työryhmä. Dyslipidemiat. Duodecim 2004; 120: 17941816 (in Finnish).
  • 26
    Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 health examination survey. Publications of the National Public Health Institute 2002; B3/2002.
  • 27
    Sakshaug S, Furu K, Karlstad Ø, Rønnig M, Skurtveit S. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br J Clin Pharmacol 2007; 64: 47681.
  • 28
    Försäljningsstatistik. Statistics on medicinal product sales. Available at (last accessed 3 August 2007).
  • 29
    Danish Medicines Agency. Medicinal Product Statistics 2001–2005. Danish Medicines Agency, Denmark: Legemiddelstyrelsen, 2006.